December 5, 2023 03:23 PM EST
Pharma
FDA+
Manufacturing

FDA sends let­ter to No­var­tis over Kym­ri­ah man­u­fac­tur­ing safe­ty con­cerns

Zachary Brennan

Senior Editor

The FDA on Tues­day re­leased a new un­ti­tled let­ter, sent in Au­gust to No­var­tis, af­ter the agency’s in­spec­tors found new and sig­nif­i­cant is­sues with how …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times